Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Jeffrey S. Weber, Ana Arance et al.|Clinical Cancer Research|2023Cited by 185
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective studyMario Mandalà, Paolo A. Ascierto, Teresa Amaral et al.|European Journal of Cancer|2025Cited by 7